Margin operasi: Organogenesis (ORGO)

Organogenesis Holdings (ORGO) is implementing automated bioreactors and semi-autonomous packaging, confirming the operational profitability of its processes, where -21.70 represents the current metric. The business foundation is based on strict FDA control and unique patents. Demand is driven by an aging population and diabetic pathologies, ensuring revenue stability regardless of economic conditions.
ORGO (Organogenesis Holdings): rincian analitis lan laporan miturut indikator

Organogenesis Holdings (ORGO) ensures a stable cash flow through the regular supply of regenerative medicine materials. This operating profit margin illustrates the efficiency of managing these resources. The metric is calculated as the ratio of operating income to revenue, excluding the impact of taxes and debt service. This chart reflects the real profitability of the core business. The growth of this metric confirms the resilience of the model and reduces investment risks.